SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-20-015118
Filing Date
2020-08-10
Accepted
2020-08-10 17:22:48
Documents
47
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 463772
2 ex31-1.htm EX-31.1 17833
3 ex32-1.htm EX-32.1 6715
  Complete submission text file 0001493152-20-015118.txt   2820168

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE FILE lixt-20200630.xml EX-101.INS 458137
5 XBRL SCHEMA FILE lixt-20200630.xsd EX-101.SCH 48932
6 XBRL CALCULATION FILE lixt-20200630_cal.xml EX-101.CAL 27673
7 XBRL DEFINITION FILE lixt-20200630_def.xml EX-101.DEF 148110
8 XBRL LABEL FILE lixt-20200630_lab.xml EX-101.LAB 288134
9 XBRL PRESENTATION FILE lixt-20200630_pre.xml EX-101.PRE 199080
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

IRS No.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51476 | Film No.: 201090408
SIC: 2834 Pharmaceutical Preparations